Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | TLR4 | O00206 | 2/20 | 0.34 |
| ▸ | AKT1 | P31749 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2270785 | 1.00 | CYP1A2 (0.47) | CYP1A2NAAAPOLBHPGDLMNA | |
| SCHEMBL15086803 | 0.95 | CYP1A2 (0.54) | CYP1A2NAAAHTTMAPTPPARG | |
| SCHEMBL2273086 | 0.95 | CYP1A2 (0.54) | CYP1A2NAAAHTTMAPTPPARG | |
| SCHEMBL2270903 | 0.95 | CYP1A2 (0.54) | CYP1A2NAAAHTTMAPTPPARG | |
| SCHEMBL2273082 | 0.95 | CYP1A2 (0.54) | CYP1A2NAAAHTTMAPTPPARG | |
| SCHEMBL2277253 | 0.95 | CYP1A2 (0.54) | CYP1A2NAAAHTTMAPTPPARG | |
| SCHEMBL2270910 | 0.95 | CYP1A2 (0.54) | CYP1A2NAAAHTTMAPTPPARG | |
| SCHEMBL12370935 | 0.93 | CYP1A2 (0.53) | CYP1A2HTTPPARGPKMCCR2 | |
| SCHEMBL2273782 | 0.91 | CYP1A2 (0.41) | CYP1A2NAAALMNAMAPTPPARG | |
| SCHEMBL2277758 | 0.91 | CYP1A2 (0.41) | CYP1A2NAAALMNAMAPTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020407-B1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | JNC CORP (JP) | 2013-07-03 | — | — | EP | claimed |
| CN-101490026-B | 2-oxetanone derivative and process for production thereof | CHISSO CORP | 2012-11-21 | — | — | CN | claimed |
| US-7999123-B2 | 2-oxetanone derivative and process for production thereof | JNC CORPORATION (JP) | 2011-08-16 | — | — | US | claimed |
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2009-11-05 | — | — | US | claimed |
| CN-101490026-A | 2-oxetanone derivative and process for production thereof | CHISSO CORP (JP) | 2009-07-22 | — | — | CN | claimed |
| EP-2020407-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | Chisso Corporation (JP) | 2009-02-04 | — | — | EP | claimed |
| EP-2020407-B1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | JNC CORP (JP) | 2013-07-03 | — | — | EP | disclosed |
| CN-101490026-B | 2-oxetanone derivative and process for production thereof | CHISSO CORP | 2012-11-21 | — | — | CN | disclosed |
| US-7999123-B2 | 2-oxetanone derivative and process for production thereof | JNC CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | CHISSO CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| CN-101490026-A | 2-oxetanone derivative and process for production thereof | CHISSO CORP (JP) | 2009-07-22 | — | — | CN | disclosed |
| EP-2020407-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | Chisso Corporation (JP) | 2009-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275756-A1 | 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF | OGDH, OXGR1, OXER1 | CYP1A2 40/4885NAAA 3308/4885POLB 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.